标题
Immunotherapies and Combination Strategies for Immuno-Oncology
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 14, Pages 5009
出版商
MDPI AG
发表日期
2020-07-16
DOI
10.3390/ijms21145009
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure
- (2020) Jordan Gauthier et al. BLOOD
- Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients
- (2020) Junxun Ma et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Resistance to Checkpoint Inhibition in Cancer Immunotherapy
- (2020) Luisa Barrueto et al. Translational Oncology
- How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
- (2020) Morgane Denis et al. Frontiers in Immunology
- Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer
- (2020) Eric X. Chen et al. JAMA Oncology
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
- (2020) Raju K. Vaddepally et al. Cancers
- Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
- (2019) Xianjie Jiang et al. Molecular Cancer
- Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
- (2019) Celeste Lebbé et al. JOURNAL OF CLINICAL ONCOLOGY
- An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.
- (2019) Yung-Jue Bang et al. JOURNAL OF CLINICAL ONCOLOGY
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
- (2019) Dinh-Toi Chu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results
- (2019) Padmanee Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
- (2019) Xinyue Qi et al. Nature Communications
- The promise of Immuno-oncology: implications for defining the value of cancer treatment
- (2019) Howard L. Kaufman et al. Journal for ImmunoTherapy of Cancer
- Combination of CTLA-4 and PD-1 blockers for treatment of cancer
- (2019) Anand Rotte JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy
- (2019) Christina Claus et al. Science Translational Medicine
- T Cell Dysfunction in Cancer Immunity and Immunotherapy
- (2019) Anliang Xia et al. Frontiers in Immunology
- Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer
- (2019) Danyang Sun et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function
- (2019) Fanny Polesso et al. JOURNAL OF IMMUNOLOGY
- OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
- (2019) Juan Deng et al. OncoTargets and Therapy
- Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted chimeric antigen receptor-T cells for B-cell non-Hodgkin lymphoma
- (2019) Zhitao Ying et al. Molecular Therapy-Oncolytics
- Therapeutic strategies for the costimulatory molecule OX40 in T-cell mediated immunity
- (2019) Yu Fu et al. Acta Pharmaceutica Sinica B
- 1190PDPhase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)
- (2019) Y Drew et al. ANNALS OF ONCOLOGY
- Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
- (2019) Xinjie Xu et al. Frontiers in Immunology
- The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
- (2019) Andrew A. Davis et al. Journal for ImmunoTherapy of Cancer
- Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers
- (2018) Cédric Rossi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer
- (2018) Russell W. Jenkins et al. Annual Review of Medicine
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy
- (2018) Jonathan Pol et al. CELL RESEARCH
- Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome
- (2018) Marie-Andrée Forget et al. CLINICAL CANCER RESEARCH
- Avelumab: A Novel Anti-PD-L1 Agent in the Treatment of Merkel Cell Carcinoma and Urothelial Cell Carcinoma
- (2018) Amanda Teets et al. CRITICAL REVIEWS IN IMMUNOLOGY
- Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T
- (2018) Dok Yoon et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses
- (2018) Ashley V. Menk et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
- (2018) Xiaolei Li et al. Journal of Hematology & Oncology
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR-T cells: the long and winding road to solid tumors
- (2018) Maria Michela D’Aloia et al. Cell Death & Disease
- Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions
- (2018) Yifan Wang et al. Frontiers in Pharmacology
- Combining immunotherapy and radiotherapy in lung cancer
- (2018) Neeraj Bhalla et al. Journal of Thoracic Disease
- Checks and Balances in Autoimmune Vasculitis
- (2018) Rebeca Hid Cadena et al. Frontiers in Immunology
- VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
- (2018) Liru Wang et al. OncoImmunology
- The application of CAR-T cell therapy in hematological malignancies: Advantages and challenges
- (2018) Zijun Zhao et al. Acta Pharmaceutica Sinica B
- Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
- (2018) John E. Mullinax et al. Frontiers in Oncology
- Durvalumab: a newly approved checkpoint inhibitor for the treatment of urothelial carcinoma
- (2018) Stephanie Wills et al. CURRENT PROBLEMS IN CANCER
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
- (2018) Ming Yi et al. Molecular Cancer
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR/ERK Activation
- (2018) Hoi Yan Ng et al. Translational Oncology
- Anti-CD20 monoclonal antibodies: reviewing a revolution
- (2018) J. M. L. Casan et al. Human Vaccines & Immunotherapeutics
- Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells
- (2018) Reza Elahi et al. Frontiers in Immunology
- CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies
- (2018) Hannah M. Knochelmann et al. Frontiers in Immunology
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Immuno-Oncology: Emerging Targets and Combination Therapies
- (2018) Henry T. Marshall et al. Frontiers in Oncology
- 1152PSafety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors
- (2018) B Glisson et al. ANNALS OF ONCOLOGY
- Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance
- (2018) Xingxiang Pu et al. BMC CANCER
- VISTA expressed in tumour cells regulates T cell function
- (2018) Kumuluzi Mulati et al. BRITISH JOURNAL OF CANCER
- Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?
- (2018) Florian Wirsdörfer et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Universal CARs, universal T cells, and universal CAR T cells
- (2018) Juanjuan Zhao et al. Journal of Hematology & Oncology
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
- (2018) Rodabe N. Amaria et al. NATURE MEDICINE
- Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
- (2018) Christian U. Blank et al. NATURE MEDICINE
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- TIM-3, a promising target for cancer immunotherapy
- (2018) Yayi He et al. OncoTargets and Therapy
- A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
- (2018) Vivek Verma et al. Journal for ImmunoTherapy of Cancer
- Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
- (2018) Maartje W. Rohaan et al. Journal for ImmunoTherapy of Cancer
- CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors
- (2018) Anna C. Filley et al. Frontiers in Oncology
- Immunotherapy and radiotherapy for metastatic cancers
- (2018) Andrew Bang et al. Annals of Palliative Medicine
- Immunoregulatory functions of VISTA
- (2017) Elizabeth C. Nowak et al. IMMUNOLOGICAL REVIEWS
- TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
- (2017) Wenwen Du et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy
- (2017) Andrew Bang et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor T Cells in Hematologic Malignancies
- (2017) Brandon R. Shank et al. PHARMACOTHERAPY
- Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations
- (2017) Margaret E. Gatti-Mays et al. Human Vaccines & Immunotherapeutics
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Global Manufacturing of CAR T Cell Therapy
- (2017) Bruce L. Levine et al. Molecular Therapy-Methods & Clinical Development
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR
- (2016) Elise A. Chong et al. BLOOD
- The growing world of CAR T cell trials: a systematic review
- (2016) Astrid Holzinger et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma
- (2016) Drew C. Deniger et al. CLINICAL CANCER RESEARCH
- The immune mechanisms of abscopal effect in radiation therapy
- (2016) G. Daniel Grass et al. CURRENT PROBLEMS IN CANCER
- Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist
- (2016) Marcela V. Maus et al. ONCOLOGIST
- Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
- (2016) Gulidanna Shayan et al. OncoImmunology
- Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk
- (2016) Jing Li et al. OncoImmunology
- Toxicity and management in CAR T-cell therapy
- (2016) Challice L Bonifant et al. Molecular Therapy-Oncolytics
- Current clinical trials testing the combination of immunotherapy with radiotherapy
- (2016) Josephine Kang et al. Journal for ImmunoTherapy of Cancer
- Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells
- (2015) B L Levine CANCER GENE THERAPY
- Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
- (2015) J. Peng et al. CANCER RESEARCH
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- Chimeric Antigen Receptor Engineering: A Right Step in the Evolution of Adoptive Cellular Immunotherapy
- (2015) Jose A. Figueroa et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
- (2015) Michele Maio et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street
- (2015) David M. Barrett et al. JOURNAL OF IMMUNOLOGY
- Tumor-infiltrating lymphocytes for the treatment of metastatic cancer
- (2015) M.H. Geukes Foppen et al. Molecular Oncology
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy
- (2014) Dass S. Vinay et al. BMB Reports
- VISTA Is an Immune Checkpoint Molecule for Human T Cells
- (2014) J. L. Lines et al. CANCER RESEARCH
- VISTA Regulates the Development of Protective Antitumor Immunity
- (2014) I. Le Mercier et al. CANCER RESEARCH
- Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma
- (2014) F. Stephen Hodi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
- (2014) C. Tang et al. Cancer Immunology Research
- VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy
- (2014) J. L. Lines et al. Cancer Immunology Research
- Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival
- (2014) Amir Khammari et al. Journal of Immunology Research
- OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
- (2013) B. D. Curti et al. CANCER RESEARCH
- Molecular Pathways: Coexpression of Immune Checkpoint Molecules: Signaling Pathways and Implications for Cancer Immunotherapy
- (2013) C. J. Nirschl et al. CLINICAL CANCER RESEARCH
- Challenges and Opportunities for Cancer Vaccines in the Current NSCLC Clinical Scenario
- (2013) Pedro Rodriguez et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Radiation and immunotherapy: a synergistic combination
- (2013) Anusha Kalbasi et al. JOURNAL OF CLINICAL INVESTIGATION
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Are the Results of RTOG 0617 Mysterious?
- (2012) James D. Cox INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
- (2012) Steffen Walter et al. NATURE MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression
- (2012) Xin Gao et al. PLoS One
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells
- (2009) Claudia Wrzesinski et al. JOURNAL OF IMMUNOTHERAPY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started